Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study.
Acute and prophylactic effects of carbamazepine are documented in a double-blind clinical trial in a 55-year-old treatment-refractory, lithium-non-responsive, manic-depressive patient. Double-blind crossover to two other anticonvulsants was also achieved; the patient showed no evidence of response to phenytoin or valproic acid. The clinical and theoretical issues raised by the selective response to carbamazepine in this patient are discussed.
D001714:Bipolar Disorder / Q000188:drug therapy*; D002220:Carbamazepine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008875:Middle Aged; D010672:Phenytoin / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D008094:Lithium